Preclinical Kv3 Modulators
Schizophrenia
Key Facts
About Autifony Therapeutics
Autifony Therapeutics is a private, clinical-stage biotech founded in 2011 as a spin-out from GlaxoSmithKline. The company's core expertise lies in translating ion channel biology into therapeutics, with two clinical-stage Kv3 modulators for Fragile X syndrome (AUT00206, with FDA Orphan Drug Designation) and rare myoclonic epilepsies (AUT00201). Beyond these lead rare disease programs, Autifony has built a broader preclinical and early-stage pipeline targeting other CNS disorders, positioning it as a specialist in neuronal excitability and hearing disorders.
View full company profileAbout Autifony Therapeutics
Autifony Therapeutics is a private, clinical-stage biotech founded in 2011 as a spin-out from GlaxoSmithKline. The company's core expertise lies in translating ion channel biology into therapeutics, with two clinical-stage Kv3 modulators for Fragile X syndrome (AUT00206, with FDA Orphan Drug Designation) and rare myoclonic epilepsies (AUT00201). Beyond these lead rare disease programs, Autifony has built a broader preclinical and early-stage pipeline targeting other CNS disorders, positioning it as a specialist in neuronal excitability and hearing disorders.
View full company profileOther Schizophrenia Drugs
| Drug | Company | Phase |
|---|---|---|
| DB103 (Pomaglumetad) | Denovo Biopharma | Phase 2b/3 |
| ZZ6398 | Zhongze Therapeutics | Phase 1/2 |
| RBP-7000 (PERSERIS®) | Indivior | Marketed |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| Schizophrenia Candidate | Teva | Phase 3 |
| Schizophrenia Model Service | NeuroProof | Pre-clinical |
| LYN-005 (Nortiva) | Lyndra | Phase 3 |
| TerXT | Terran Biosciences | Late-stage (Pre-Phase 3) |
| Undisclosed Program | Curemark | Preclinical |
| Schizophrenia Intermediate | OFD Biopharma | Proof of concept |
| Schizophrenia | Keltic Pharma Therapeutics | Pre-clinical |
| AVAT-031 | Avata Biosciences | Discovery |